Drug-resistant tuberculosis in Mumbai, India: An agenda for operations research

Operations Research for Health Care

Volumn 1, Issue 2-3, 2012, Pages 45-53

  Mistry, Nerges ^a   Tolani, Monica ^a   Osrin, David ^b  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Global health; Public health; Tuberculosis

Indexed keywords

EID: 84867210346     PISSN: 22116923     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.orhc.2012.06.001     Document Type: Article

References (125)

1. Datta S. Applications of OR in health in developing countries: a review. Soc. Sci. Med. 1993, 37:1441-1450.
2. White L., Smith H., Currie C. OR in developing countries: a review. Eur. J. Opl. Res. 2011, 208:1-11.
3. Royston G. Meeting global health challenges through operational research and management science. Bull. World Health Organ. 2011, 89:683-688.
4. Laserson K.F., Binkin N.J., Thorpe L.E., Laing R., Iademarco M.F., Bloom A., et al. Capacity building for international tuberculosis control through operations research training. Int. J. Tuberc. Lung Dis. 2005, 9:145-150.
5. Zachariah R., Harries A.D., Ishikawa N., Rieder H.L., Bissell K., Laserson K., et al. Operational research in low-income countries: what, why, and how?. Lancet. Infect. Dis. 2009, 9:711-717.
6. Harries A.D., Rusen I.D., Reid T., Detjen A.K., Berger S.D., Bissell K., et al. The union and Medecins Sans Frontieres approach to operational research. Int. J. Tuberc. Lung Dis. 2011, 15:144-154.
7. Nunn P., Harries A., Godfrey-Faussett P., Gupta R., Maher D., Raviglione M. The research agenda for improving health policy, systems performance and service delivery for tuberculosis control: a WHO perspective. Bull. World Health Organ. 2002, 80:471-476.
8. Zachariah R., Ford N., Maher D., Bissell K., Van den Bergh R., van den Boogaard W., et al. Is operational research delivering the goods? the journey to success in low-income countries. Lancet. Infect. Dis. 2012.
9. Zumla A., Cobelens F. Operational research and MDG tuberculosis control targets. Lancet. Infect. Dis. 2012, 12:262-263.
10. Stop TB Partnership, Global Fund. Priorities in operational research to improve tuberculosis care and control. Geneva: World Health Organization. Global Fund to Fight AIDS, Tuberculosis and Malaria, 2011.
11. Lienhardt C., Cobelens F.G.J. Operational research for improved tuberculosis control: the scope, the needs and the way forward. Int. J. Tuberc. Lung Dis. 2011, 15:6-13.
12. Harries A.D. Integration of operational research into national tuberculosis control programmes. Tuberc. 2003, 83:143-147.
13. Marais B.J., Raviglione M.C., Donald P.R., Harries A.D., Kritski A.L., Graham S.M., et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 2010, 375(9732):2179-2191.
14. WHO, Stop TB Partnership. The Stop TB Strategy. WHO/HTM/TB/2006.368. Geneva, 2006.
15. Stop TB Partnership, WHO. The global plan to stop TB, 2011-2015, Geneva, World Health Organization, 2010.
16. WHO. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, World Health Organization, 2011.
17. Central TB Division. TB India 2011. Revised national TB control programme - annual status report. New Delhi: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2011.
18. Census of India. New Delhi: Office of the Registrar General and Census Commissioner, India, 2001. http://www.censusindia.gov.in/.
19. Municipal Corporation of Greater Mumbai Mumbai Human Development Report 2009 2010, Oxford University Press, New Delhi.
20. Atun R., Raviglione M., Marais B., Zumla A. Tuberculosis control is crucial to achieve the MDGs. Lancet 2010, 376:940-941.
21. United Nations Human Settlements Programme (UN-Habitat) The Challenge of Slums: Global Report on Human Settlements 2003 2003, Earthscan Publications Ltd, London and Sterling VA.
22. K. Gupta, F. Arnold, H. Lhungdim, Health and living conditions in eight Indian cities. National Family Health Survey (NFHS-3), India, 2005-06. Mumbai, International Institute for Population Sciences, 2009.
23. Diamond J. Diabetes in India. Nature 2011, 469:469-479.
24. Udwadia Z.F., Pinto L.M., Uplekar M.W. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?. PLoS One 2010, 5(8):e12023.
25. Almeida D., Rodrigues C., Udwadia Z.F., Lalvani A., Gothi G.D., Mehta P., et al. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin. Infect. Dis. 2003, 36:152-154.
26. D'Souza D.T., Mistry N.F., Vira T.S., Dholakia Y., Hoffner S., Pasvol G., et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the revised national tuberculosis control programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009, 9:211.
27. Chowgule R.V., Deodhar L. Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India-1991-1995. Indian J. Chest Dis. Allied Sci. 1998, 40(1):23-31.
28. Negi S.S., Gupta S., Lal S. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001-2002). J. Commun. Dis. 2003, 35(2):74-81.
29. Santha T., Thomas A., Chandrasekaran V., Selvakumar N., Gopi P.G., Subramani R., et al. Initial drug susceptibility profile of M. tuberculosis among patients under TB programme in South India. Int. J. Tuberc. Lung Dis. 2006, 10(1):52-57.
30. Jain A., Mondal R., Prasad R., Singh K., Ahuja R.C. Prevalence of multidrug resistant Mycobacterium tuberculosis in Lucknow, Uttar Pradesh. Indian J. Med. Res. 2008, 128(3):300-306.
31. Aparna S.B., Reddy V.C., Gokhale S., Moorthy K.V. In vitro drug resistance and response to therapy in pulmonary tuberculosis patients under a DOTS programme in South India. Trans. R. Soc. Trop. Med. Hyg. 2009, 103(6):564-570.
32. Ramachandran R., Nalini S., Chandrasekar V., Dave P.V., Sanghvi A.S., Wares F., et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int. J. Tuberc. Lung Dis. 2009, 13(9):1154-1160.
33. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, World Health Organization, 2010.
34. Sharma S.K., Kaushik G., Jha B., George N., Arora S.K., Gupta D., et al. Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J. Med. Res. 2011, 133:308-311.
35. Sharma S.K., Kumar S., Saha P.K., George N., Arora S.K., Gupta D., et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J. Med. Res. 2011, 133:312-315.
36. Udwadia Z.F., Jain S., Rodrigues C., Mehta A. XDR tuberculosis in India: what's in a name?. Lancet. Infect. Dis. 2007, 7(7):441-442.
37. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012, 54(4):579-581.
38. Udwadia Z.F. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 2012, 67(4):286-288.
39. RNTCP. Operational research guidelines and action plan. New Delhi, Revised National Tuberculosis Control Programme, 2009.
40. Atre S.R., D'Souza D.T., Dholakia Y.N., Mistry N.F. Observations on categorisation of new TB cases: implications for controlling drug resistance. Int. J. Tuberc. Lung Dis. 2007, 11(10):1152-1153.
41. Kaul S. An Observational Study of RNTCP and DOTS Strategy in Three Districts 1998, Voluntary Health Association of India, New Delhi.
42. Mehra R.K., Dhingra V.K., Nish A., Vashist R.P. Study of relapse and failure cases of CAT I retreated with CAT II under RNTCP - an eleven year follow up. Indian J. Tuberc. 2008, 55(4):188-191.
43. Sachdeva K.S., Satyanarayana S., Dewan P.K., Nair S.A., Reddy R., Kundu D., et al. Source of previous treatment for re-treatment TB cases registered under the national TB control programme, India, 2010. PLoS One 2011, 6(7):e22061.
44. Mukherjee A., Sarkar A., Saha I., Biswas B., Bhattacharyya P.S. Outcomes of different subgroups of smear-positive retreatment patients under RNTCP in rural West Bengal, India. Rural Remote Health 2009, 9(1):926.
45. Hanif M., Malik S., Dhingra V.K. Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int. J. Tuberc. Lung Dis. 2009, 13(1):74-78.
46. Bhatia J., Cleland J. Health-care seeking and expenditure by young Indian mothers in the public and private sectors. Health Policy Plan. 2001, 16:55-61.
47. N. Barua, How to develop a pro-poor private health sector in urban India? Global Forum for Health Research. Forum 9, Mumbai, 2005.
48. PriceWaterhouseCoopers. Healthcare in India: emerging market report 2007, 2007.
49. Ambe G., Lonnroth K., Dholakia Y., Copreaux J., Zignol M., Borremans N., et al. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int. J. Tuberc. Lung Dis. 2005, 9(5):562-568.
50. Garner P., Thaver I. Urban slums and primary health care. the private doctor's role. BMJ 1993, 306:667-668.
51. Madhiwalla N. Hospitals and city health. Bombay and Mumbai: The City in Transition 2003, Oxford University Press, New Delhi. S. Patel, J. Masselos (Eds.).
52. T.R. Dilip, R. Duggal, Demand for public health services in Mumbai. Mumbai: Center for Enquiry into Health and Allied Themes, 2003.
53. Babu G.R., Laxminarayan R. The unsurprising story of MDR-TB resistance in India. Tuberc. 2012.
54. Kelkar-Khambete A., Kielmann K., Pawar S., Porter J., Inamdar V., Datye A., et al. India's revised national tuberculosis control programme: looking beyond detection and cure. Int. J. Tuberc. Lung Dis. 2008, 12(1):87-92.
55. Charles N., Thomas B., Watson B., Raja Sakthivel M., Chandrasekeran V., Wares F. Care seeking behavior of chest symptomatics: a community based study done in South India after the implementation of the RNTCP. PLoS One 2010, 5(9).
56. Satyanarayana S., Nair S.A., Chadha S.S., Shivashankar R., Sharma G., Yadav S., et al. From where are tuberculosis patients accessing treatment in India? results from a cross-sectional community based survey of 30 districts. PLoS One 2011, 6(9):e24160.
57. Balasubramanian R., Garg R., Santha T., Gopi P.G., Subramani R., Chandrasekaran V., et al. Gender disparities in tuberculosis: report from a rural DOTS programme in South India. Int. J. Tuberc. Lung Dis. 2004, 8(3):323-332.
58. Dandona R., Dandona L., Mishra A., Dhingra S., Venkatagopalakrishna K., Chauhan L.S. Utilization of and barriers to public sector tuberculosis services in India. Natl. Med. J. India 2004, 17(6):292-299.
59. Uplekar M., Pathania V., Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet. 2001, 358(9285):912-916.
60. Fochsen G., Deshpande K., Diwan V., Mishra A., Diwan V.K., Thorson A. Health care seeking among individuals with cough and tuberculosis: a population-based study from rural India. Int. J. Tuberc. Lung Dis. 2006, 10(9):995-1000.
61. Jaggarajamma K., Balambal R., Muniyandi M., Vasantha M., Thomas B., Nirupa C., et al. Perceptions of tuberculosis patients about private providers before and after implementation of revised national tuberculosis control programme. Indian J. Tuberc. 2009, 56(4):185-190.
62. Pradhan A., Kielmann K., Gupte H., Bamne A., Porter J.D., Rangan S. What 'outliers' tell us about missed opportunities for tuberculosis control: a cross-sectional study of patients in Mumbai, India. BMC Public Health 2010, 10:263.
63. Dewan P.K., Lal S.S., Lonnroth K., Wares F., Uplekar M., Sahu S., et al. Improving tuberculosis control through public-private collaboration in India: literature review. BMJ 2006, 332(7541):574-578.
64. Arora V.K., Gupta R. Private-public mix: a prioritisation under RNTCP-an Indian perspective. Indian J. Chest Dis. Allied Sci. 2004, 46(1):27-37.
65. Floyd K., Arora V.K., Murthy K.J., Lonnroth K., Singla N., Akbar Y., et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull. World Health Organ. 2006, 84(6):437-445.
66. Krishnan A., Kapoor S.K. Involvement of private practitioners in tuberculosis control in Ballabgarh, Northern India. Int. J. Tuberc. Lung Dis. 2006, 10(3):264-269.
67. Agarwal S.P., Chauhan L.S. Tuberculosis Control in India 2005, Ministry of Health and Family Welfare, New Delhi.
68. Swaminathan S., Ramachandran R., Baskaran G., Paramasivan C.N., Ramanathan U., Venkatesan P., et al. Risk of development of tuberculosis in HIV-infected patients. Int. J. Tuberc. Lung Dis. 2000, 4(9):839-844.
69. UNAIDS. 2007 AIDS epidemic update. UNAIDS/07.27E/JC1322E. Geneva, Joint United Nations Programme on HIV/AIDS, 2007.
70. Dewan P.K., Gupta D., Williams B.G., Thakur R., Bachani D., Khera A., et al. National estimate of HIV seroprevalence among tuberculosis patients in India. Int. J. Tuberc. Lung Dis. 2010, 14(2):247-249.
71. Grandin W., Dev A.V., Latha A., Armstrong L., Mathai D., John K.R., et al. Detection of human immunodeficiency virus infection in the sputum of tuberculosis patients in South India. Int. J. Tuberc. Lung Dis. 2010, 14(10):1288-1294.
72. RNTCP. Revised National Tuberculosis Control Programme (RNTCP) Performance report, India. Second quarter, 2011. New Delhi, Central TB Division, Directorate General of Health Services, 2011.
73. Ramachandran R., Datta M., Subramani R., Baskaran G., Paramasivan C.N., Swaminathan S. Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu. Indian J. Med. Res. 2003, 118:147-151.
74. Hussain T., Sinha S., Kulshreshtha K.K., Yadav V.S., Sharma P., Sengupta U., et al. Seroprevalence of HIV infection among tuberculosis patients in Agra, India - a hospital-based study. Tuberculosis (Edinb.) 2006, 86(1):54-59.
75. Piramanayagam P., Tahir M., Sharma S.K., Smith-rohrberg D., Biswas A., Vajpayee M. Persistently high HIV seroprevalence among adult tuberculosis patients at a tertiary care centre in Delhi. Indian J. Med. Res. 2007, 125(2):163-167.
76. Raizada N., Chauhan L.S., Khera A., Sokhey J., Wares D.F., Sahu S., et al. HIV seroprevalence among tuberculosis patients in India, 2006-2007. PLoS One 2008, 3(8):e2970.
77. Raizada N., Chauhan L.S., Babu B.S., Thakur R., Khera A., Wares D.F., et al. Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India. PLoS One 2009, 4(6):e5999.
78. Padmapriyadarsini C., Narendran G., Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J. Med. Res. 2011, 134(6):850-865.
79. Isaakidis P., Cox H.S., Varghese B., Montaldo C., Da Silva E., Mansoor H., et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One 2011, 6(12):e28066.
80. Mboussa J., Monabeka H., Kombo M., Yokolo D., Yoka-Mbio A., Yala F. Course of pulmonary tuberculosis in diabetics. Rev. Pneumol. Clin. 2003, 59(1):39-44.
81. Shetty N., Shemko M., Vaz M., D'Souza G. An epidemiological evaluation of risk factors for tuberculosis in South India: a matched case control study. Int. J. Tuberc. Lung Dis. 2006, 10(1):80-86.
82. Coker R., McKee M., Atun R., Dimitrova B., Dodonova E., Kuznetsov S., et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006, 332(7533):85-87.
83. Jabbar A., Hussain S.F., Khan A.A. Clinical characteristics of pulmonary tuberculosis in adult Pakistani patients with co-existing diabetes mellitus. East Mediterr. Health J. 2006, 12(5):522-527.
84. Goldhaber-Fiebert J.D., Jeon C.Y., Cohen T., Murray M.B. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int. J. Epidemiol. 2011, 40(2):417-428.
85. Ezung T., Devi N.T., Singh N.T., Singh T.B. Pulmonary tuberculosis and diabetes mellitus - a study. J. Indian Med. Assoc. 2002, 100(6):376. 8-9.
86. Gupta S., Shenoy V.P., Mukhopadhyay C., Bairy I., Muralidharan S. Role of risk factors and socio-economic status in pulmonary tuberculosis: a search for the root cause in patients in a tertiary care hospital, South India. Trop. Med. Int. Health 2011, 16(1):74-78.
87. Stevenson C.R., Forouhi N.G., Roglic G., Williams B.G., Lauer J.A., Dye C., et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007, 7:234.
88. Dye C., Bourdin Trunz B., Lonnroth K., Roglic G., Williams B.G. Nutrition, diabetes and tuberculosis in the epidemiological transition. PLoS One 2011, 6(6):e21161.
89. Bashar M., Alcabes P., Rom W.N., Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001, 120(5):1514-1519.
90. Banu Rekha V.V., Balasubramanian R., Swaminathan S., Ramachandran R., Rahman F., Sundaram V., et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors. Indian J. Med. Res. 2007, 126(5):452-458.
91. Fisher-Hoch S.P., Whitney E., McCormick J.B., Crespo G., Smith B., Rahbar M.H., et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand. J. Infect. Dis. 2008, 40(11-12):888-893.
92. Tanrikulu A.C., Hosoglu S., Ozekinci T., Abakay A., Gurkan F. Risk factors for drug resistant tuberculosis in southeast Turkey. Trop. Doct. 2008, 38(2):91-93.
93. Suarez-Garcia I., Rodriguez-Blanco A., Vidal-Perez J.L., Garcia-Viejo M.A., Jaras-Hernandez M.J., Lopez O., et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid. Spain. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28(4):325-330.
94. Subhash H.S., Ashwin I., Mukundan U., Danda D., John G., Cherian A.M., et al. Drug resistant tuberculosis in diabetes mellitus: a retrospective study from south India. Trop. Doct. 2003, 33(3):154-156.
95. Gupta A., Mathuria J.P., Singh S.K., Gulati A.K., Anupurba S. Antitubercular drug resistance in four healthcare facilities in North India. J. Health Popul. Nutr. 2011, 29(6):583-592.
96. WHO. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, World Health Organization, 2011.
97. Uplekar M.W., Shepard D.S. Treatment of tuberculosis by private general practitioners in India. Tubercle. 1991, 72(4):284-290.
98. Anandhi C.L., Nagaraj V.K., Kumar R. Knowledge and practice pattern of non-allopathic indigenous medical practitioners regarding tuberculosis in a rural area of India. Int. J. Tuberc. Lung Dis. 2002, 6(6):553-555.
99. Prasad R., Nautiyal R.G., Mukherji P.K., Jain A., Singh K., Ahuja R.C. Treatment of new pulmonary tuberculosis patients: what do allopathic doctors do in India?. Int. J. Tuberc. Lung Dis. 2002, 6(10):895-902.
100. Singh V., Jaiswal A., Porter J.D., Ogden J.A., Sarin R., Sharma P.P., et al. TB control, poverty, and vulnerability in Delhi, India. Trop. Med. Int. Health 2002, 7(8):693-700.
101. Laserson K.F., Kenyon A.S., Kenyon T.A., Layloff T., Binkin N.J. Substandard tuberculosis drugs on the global market and their simple detection. Int. J. Tuberc. Lung Dis. 2001, 5(5):448-454.
102. Kelesidis T., Kelesidis I., Rafailidis P.I., Falagas M.E. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J. Antimicrob. Chemother. 2007, 60(2):214-236.
103. SEARPharm Forum. Database on the incidents of counterfeit medicines in the WHO-SEA Region, 2010. http://www.searpharm.org/resources/Publication_CFM_2010.pdf.
104. Jaiswal A., Singh V., Ogden J.A., Porter J.D., Sharma P.P., Sarin R., et al. Adherence to tuberculosis treatment: lessons from the urban setting of Delhi, India. Trop. Med. Int. Health. 2003, 8(7):625-633.
105. Jaggarajamma K., Sudha G., Chandrasekaran V., Nirupa C., Thomas A., Santha T., et al. Reasons for non-compliance among patients treated under Revised National Tuberculosis Control Programme (RNTCP), Tiruvallur district, south India. Indian J. Tuberc. 2007, 54(3):130-135.
106. Bagchi S., Ambe G., Sathiakumar N. Determinants of poor adherence to anti-tuberculosis treatment in Mumbai, India. Int. J. Prev. Med. 2010, 1(4):223-232.
107. Jha U.M., Satyanarayana S., Dewan P.K., Chadha S., Wares F., Sahu S., et al. Risk factors for treatment default among re-treatment tuberculosis patients in India, 2006. PLoS One 2010, 5(1):e8873.
108. WHO. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. Geneva: World Health Organization, 1999.
109. Centers for Disease Control and Prevention. Outbreak of multidrug-resistant tuberculosis at a hospital - New York City, 1991. MMWR. 42 (22) (1993) 427-34.
110. Pai M., Kalantri S., Aggarwal A.N., Menzies D., Blumberg H.M. Nosocomial tuberculosis in India. Emerg. Infect. Dis. 2006, 12(9):1311-1318.
111. Aggarwal A.N. Tuberculosis transmission at healthcare facilities in India. Lung India 2009, 26:33-34.
112. Christopher D.J., Daley P., Armstrong L., James P., Gupta R., Premkumar B., et al. Tuberculosis infection among young nursing trainees in South India. PLoS One 2010, 5(4):e10408.
113. Christopher D.J., James P., Daley P., Armstrong L., Isaac B.T., Thangakunam B., et al. High annual risk of tuberculosis infection among nursing students in South India: a cohort study. PLoS One 2011, 6(10):e26199.
114. Chadha V.K., Kumar P., Jagannatha P.S., Vaidyanathan P.S., Unnikrishnan K.P. Average annual risk of tuberculous infection in India. Int. J. Tuberc. Lung Dis. 2005, 9(1):116-118.
115. Rao K.G., Aggarwal A.N., Behera D. Tuberculosis among physicians in training. Int. J. Tuberc. Lung Dis. 2004, 8(11):1392-1394.
116. Chadha S.S., BN S., Reddy K., Jaju J., PH V., Rao S., et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS ONE 2011, 6(11):e26659.
117. Vassall A., van Kampen S., Sohn H., Michael J.S., John K.R., den Boon S., et al. Rapid diagnosis of tuberculosis with the xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8(11):e1001120.
118. ® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int. J. Tuberc. Lung Dis. 2011, 15:1567-1571.
119. WHO. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO/HTM/TB/2011.3. Geneva: World Health Organization, 2011.
120. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO/HTM/TB/2011.6. Geneva, World Health Organization, 2011.
121. NACO, CTD. National framework for joint HIV/TB collaborative activities. New Delhi, National AIDS Control Organization and Central TB Division, Ministry of Health & Family Welfare, Government of India, 2009.
122. NACO. Annual report 2010-11. New Delhi: Department of AIDS Control, Ministry of Health & Family Welfare, Government of India, 2011.
123. WHO. Anti-tuberculosis drug resistance in the world. Fourth global report, 2008. WHO/HTM/TB/2008.394. Geneva: World Health Organization, 2008.
124. Central TB Division. Training course for program manager (Modules 1-4). Module 3: Treatment services. New Delhi: Revised National TB Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2011.
125. Basu S., Galvani A.P. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. Epidemiol. Infect. 2008, 136:1585-1598.